TomoTherapy Expands Into Central America

MADISON, WI--(Marketwire - February 16, 2011) - TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that it has expanded its worldwide presence into Central America, with the introduction of TomoTherapy(SM) treatments at the International Cancer Center of El Salvador in San Salvador. With the opening of this new center, TomoTherapy® systems are now available in 24 countries around the world.

The International Cancer Center installed a TomoTherapy Hi-Art® treatment system, which enables clinicians there to deliver highly precise image-guided, intensity-modulated radiation therapy (IG-IMRT) to disease sites. The TomoTherapy Hi-Art treatment system integrates CT imaging and radiation delivery technology. Using the system, clinicians can efficiently acquire a low-dose helical CT image immediately before each daily treatment in order to ensure precise patient positioning. The same machine is then used to deliver radiation in a continuous, 360-degree pattern around the patient’s body, enabling effective targeting of the tumor while minimizing damage to healthy surrounding tissue and critical structures.

“Historically, El Salvador has lagged behind other Latin and Central American countries in its ability to treat cancer with radiation therapy. As a result, we wanted to bring the best resources available to treat cancer to our new center,” said Dr. Rodrigo Brito, CEO of the International Cancer Center. “We believe the TomoTherapy Hi-Art system offers the most integrated, advanced radiation therapy technology in the world and allows us to provide a unique and effective treatment to patients in these regions. Now, with our TomoTherapy system, we are able to position our center ahead of those in countries like Brazil, Chile and Colombia.”

The International Cancer Center expects to treat a wide variety of cancers with its TomoTherapy system. “TomoTherapy technology offers many technical advantages over conventional radiation therapy devices, but of particular importance to us is its clinical versatility,” said Dr. Eduardo Lovo, a neurosurgeon and medical director at the International Cancer Center. “Because the system is so flexible, it will provide us efficiencies in delivering high quality treatments in standard and hypofractionated regimens for a wide range of tumors -- such as those in the brain, spine, liver, prostate and lung.”

“The advantages offered by the TomoTherapy technology are being recognized worldwide, and we are excited to bring the platform’s unique capabilities to patients in Central America for the first time through the International Cancer Center, in partnership with our distributor Medytec,” said Fred Robertson, TomoTherapy’s president and CEO. “The introduction of TomoTherapy treatments provides patients in El Salvador with a level of care that was not previously possible in any Central or South American nation.”

TomoTherapy technology is developed and manufactured by TomoTherapy Inc. and is exclusively distributed in Mexico and Central America by Medicina y Tecnologia S.A. de C.V. (Medytec), a Mexico-based provider of advanced medical technology.

To celebrate the milestone of being the first group to bring advanced TomoTherapy treatments to Central and South America, the International Cancer Center will host an opening ceremony today. More than 500 guests are expected to attend.

About the International Cancer Center of El Salvador
The Diagnostic Hospital’s International Cancer Center of El Salvador is the first institution in Central and South America to offer radiation therapy using the advanced TomoTherapy® platform. It is also the only institution in El Salvador that offers a comprehensive range of treatment modalities, including: surgery; radiosurgery; nutritional support; emotional support; pain management; rehabilitation; and reconstructive surgery. The team at the International Cancer Center uses a holistic, multidisciplinary approach to treating the disease, including physical, psychological, emotional support, and a focus on education and prevention. For more information please visit: www.centrodecancer.com.sv

About Medicina y Tecnologia S.A. de C.V. (Medytec)
Medicina y Tecnologia S.A. de C.V. (Medytec) is a distributor and supplier of high technology medical equipment, including services and clinical training, for radiation oncology manufacturers. Medytec has introduced leading edge technology to a number of centers throughout Latin America. Find more information at Medytecmex.com.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its Hi-Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2011 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, Hi-Art, TomoHD and the TomoTherapy logo are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.


Investor Contact:
Thomas E. Powell
Chief Financial Officer
608.824.2800
Email Contact

Media Contacts:
Kevin O’Malley
Director, Corporate Communications
608.824.3384
Email Contact

Susan Lehman
Rockpoint Public Relations
510.832.6006
Email Contact

MORE ON THIS TOPIC